EDMONTON, Alberta, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today announces the change of its Chief Executive Officer (CEO). Effective November 23, 2026, Dr. Madi Madiyalakan will be retiring from his position as Quest’s CEO. Dr. Madiyalakan has been the CEO of Quest since August 2006. Mr. Jeffrey Shon, a director of Quest, will be taking over the role of CEO. Mr. Shon has considerable experience in the areas of legal, regulatory and corporate affairs, including venture capital funding focused on emerging technologies.

J. Mark Lievonen, Chairman of Quest’s Board, stated, “We thank Dr. Madiyalakan for his tireless efforts, hard work and unwavering loyalty to Quest over the past 20 years, and we wish him all the best in his future endeavors. We welcome Mr. Shon, as CEO of Quest following Dr. Madiyalakan’s retirement, and wish him success in his efforts to run the Company and create shareholder value.”

Globenewswire